Immune checkpoint blockade(ICB)therapies exhibit substantial clinical benefit in different cancers,but relatively low response rates in the majority of patients highlight the need to understand mutual relationships am...Immune checkpoint blockade(ICB)therapies exhibit substantial clinical benefit in different cancers,but relatively low response rates in the majority of patients highlight the need to understand mutual relationships among immune features.Here,we reveal overall positive correlations among immune checkpoints and immune cell populations.Clinically,patients benefiting from ICB exhibited increases for both immune stimulatory and inhibitory features after initiation of therapy,suggesting that the activation of the immune microenvironment might serve as the biomarker to predict immune response.As proof-of-concept,we demonstrated that the immune activation score(ISD)based on dynamic alteration of interleukins in patient plasma as early as two cycles(4-6 weeks)after starting immunotherapy can accurately predict immunotherapy efficacy.Our results reveal a systematic landscape of associations among immune features and provide a noninvasive,cost-effective,and time-efficient approach based on dynamic profiling of pre-and on-treatment plasma to predict immunotherapy efficacy.展开更多
基金supported by grants from the National Key Research and Development Program of China(no.2019YFA0111600 and no.2019YFE0120800 to H.L.)the National Natural Science Foundation of China(no.82073145 to Y.Y.,no.31800979 to H.L.,no.81902149 to Q.G.,and no.82102891 to X.K.)+5 种基金the Natural Science Foundation of China for outstanding Young Scholars(no.82022060 to H.L.)the Shanghai Pujiang Program(no.20PJ1412800 to Y.Y.)the Natural Science Foundation of Shanghai(no.20ZR1472900 to Y.Y.)the Natural Science Foundation of Hunan Province for outstanding Young Scholars(no.2019JJ30040 to H.L.)the Natural Science Foundation of Hunan Province of China(no.2018SK2082 to H.L.)the Scientific Research Project of Hunan Health and Family Planning Commission(no.B20180855 to H.L.).
文摘Immune checkpoint blockade(ICB)therapies exhibit substantial clinical benefit in different cancers,but relatively low response rates in the majority of patients highlight the need to understand mutual relationships among immune features.Here,we reveal overall positive correlations among immune checkpoints and immune cell populations.Clinically,patients benefiting from ICB exhibited increases for both immune stimulatory and inhibitory features after initiation of therapy,suggesting that the activation of the immune microenvironment might serve as the biomarker to predict immune response.As proof-of-concept,we demonstrated that the immune activation score(ISD)based on dynamic alteration of interleukins in patient plasma as early as two cycles(4-6 weeks)after starting immunotherapy can accurately predict immunotherapy efficacy.Our results reveal a systematic landscape of associations among immune features and provide a noninvasive,cost-effective,and time-efficient approach based on dynamic profiling of pre-and on-treatment plasma to predict immunotherapy efficacy.
